Repligen | RGEN - Le Bénéfice D'Exploitation

Prix De L'Action
102.87
Variation Quotidienne
-0.51 -0.49%
Mensuellement
-19.06%
Annuel
-18.68%
Q2 Prévisions
100.80




Le Bénéfice D'Exploitation Changement Date
Agilent USD 353M 90M 2025-12
Align Technology USD 178.05M 46.66M 2026-03
Bio Techne USD 75.49M 21.03M 2026-03
BioMarin Pharmaceutical USD 129.65M 68.74M 2026-03
Bristol-Myers Squibb USD 4.2B 562M 2025-12
Bruker USD 10.2M 66.1M 2026-03
Charles River Laboratories USD 119.9M 44.08M 2026-03
Danaher USD 1.34B 158M 2026-03
Dentsply International USD 32M 506M 2026-03
General Electric Aerospace USD 2.32B 549M 2026-03
Henry Schein USD 182M 4M 2026-03
Illumina USD 239M 17M 2026-03
IQVIA Holdings USD 565M 2.11B 2026-03
Mettler Toledo International USD 233.93M 118M 2026-03
Myriad Genetics USD -3M 20.3M 2025-12
OraSure Technologies USD -13.59M 2.13M 2025-12
Pacific Biosciences Of California USD -53.19M 35.08M 2025-12
Pfizer USD 4.99B 340M 2026-03
Repligen USD 19.98M 13K 2026-03
Revvity USD 82.77M 63.06M 2026-03
Standard Biotools USD -21.92M 1.55M 2025-12
Thermo Fisher Scientific USD 1.91B 389M 2026-03
Waters USD 148M 122.52M 2026-03
West Pharmaceutical Services USD 177.1M 14.6M 2026-03